Page 62 - Aet News Today

Ventyx Biosciences is stopping work on its lead drug candidate in plaque psoriasis and psoriatic arthritis. Despite achieving the goals of its Phase 2 test in psoriasis, the results are short of those achieved by big pharmaceutical companies with molecules that address the same target.

My phone chimed with a notification, signaling the availability of a new CT test result in my online health portal. “Multiple bilateral pulmonary nodules measuring up to 8mm. May represent metastatic disease.” This was several weeks after my very first mammogram–which I underwent shortly after my 40th birthday–detected an anomaly on my left breast. I soon learned I had what are called “dense” breasts, which means I have compact breast tissue and typical imaging isn’t the best scre...

Baylor Medicine teamed up with Luna to launch a program expanding access to in-home physical therapy for patients in the Houston area. Luna, a provider of in-home physical therapy, has similar partnerships with more than two dozen health systems. These partnerships help health systems expand access to care and increase their geographic coverage across their markets, said Palak Shah, Luna’s co-founder.

The Federal Trade Commission says more than 100 patents from 10 biopharma companies are improperly listed in the FDA’s official publication of approved products. Such listings delay generic competition, which reduces consumer choice and keeps prices high, the regulator said.

Perhaps more of us would find greater joy and fulfillment at work, if we embraced the idea of being a beginner and starting anew. The most fulfilling path in the 21st century isn’t necessarily a straight line.

Covera Health has finalized its acquisition of CoRead, the companies announced last week but did not disclose the terms of the deal. Covera also announced that it raised up to $50 million in additional Series C funding led by Insight Partners.

CMS proposed a new rule that would set a flat amount — $632 — that MA plans can pay agents and brokers when they help enroll a person into any MA plan. The proposed rule also addresses behavioral health access and prior authorization.

The “right” investment banker for you with the appropriate experience can not only tell you what your company is worth, they can also utilize their expertise to establish and run an appropriate, bespoke transaction process that will serve to reduce risk and maximally benefit you and your company’s future potential, valuation or even sale price – and they should be equally willing and able to

Medicare needs to incentivize providers by reimbursing them for identifying and addressing social determinants of health. Doing so will ultimately improve patient health outcomes and simultaneously save risk-bearing organizations money.

Bristol Myers Squibb is expanding its scope in cancer by acquiring rights to a Phase 1-ready Orum Therapeutics program that brings a new twist to antibody drug conjugates. The deal is the latest business development move in the hot field of ADCs.